Find the patients your therapy was built for.

Arima Genomics helps biopharma partners uncover structural mechanisms that define new biomarkers, reveal additional patient populations, and expand therapy-selection opportunities.

Our Hi-C sequencing technology can support programs focused on noncanonical fusions, enhancer hijacking, ecDNA, and other cancer-driving structural events — helping connect genomic mechanisms to therapeutic strategy.

We can help your team:

• Identify biomarker-defined patient populations

• Explore indication expansion opportunities

• Characterize structural mechanisms of oncogene activation

• Support translational and clinical development strategies

• Generate evidence for therapy-selection approaches